Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1503518/000104746916015101/a2229524z10-k.htm
Exhibit 99.1
|
21ST CENTURY ONCOLOGY HOLDINGS, INC.
21st Century Oncology Contact: |
Investor Contact: |
LeAnne M. Stewart |
The Ruth Group |
Chief Financial Officer |
Nick Laudico |
239-931-7281 |
646-536-7030 |
leanne.stewart@21co.com |
nlaudico@theruthgroup.com |
|
|
|
Brandon Vazquez |
|
646-536-7032 |
|
bvazquez@theruthgroup.com |
21ST CENTURY ONCOLOGY HOLDINGS INC. REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS
COMPLETES FINANCIAL RESTATEMENT
FORT MYERS, FL, August XX, 2016 21st Century Oncology Holdings, Inc. (21C or the Company), the leading global, physician-led provider of integrated cancer care services, announced today its financial results for the fourth quarter and full year ended December 31, 2015 and announced the completion of the restatement of financial results for the years ended December 31, 2012, 2013 and 2014, the unaudited condensed consolidated financial statements as of and for each of the interim periods within the years ended December 31, 2012, 2013 and 2014 and for the interim periods ended March 31, June 30, and September 30, 2015.
Fourth Quarter 2015 and Full Year 2015 Results
Total revenues for the fourth quarter of 2015 were $263.1 million, down 1.3% as compared to total revenues of $266.6 million in the same quarter of 2014. Revenue growth from acquired and new operations was offset by approximately $3.3 million relative to the effect of simulation code bundling. Net income for the fourth quarter was $7.0 million versus a net loss of $28.3 million for the same period in the prior year. The improvement in net income resulted from a fair market value adjustment for embedded derivatives.
Pro-forma adjusted EBITDA in the fourth quarter of 2015 was $38.8 million, or 14.7% of total pro-forma revenues, as compared to $30.7 million, or 11.5% of total pro-forma revenues, in the fourth quarter of 2014. The primary contributor to the pro-forma adjusted EBITDA improvement was a $6.2 million reduction in compensation expense and $5.1 million improvement in bad debt offset by the $3.5 million decrease in total revenues.
Total radiation oncology treatments per day during the fourth quarter increased 1.8% over the same period in the prior year and same market radiation oncology treatments per day for the quarter declined 2.0% compared to the same period in the prior year. As previously disclosed,
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by 21St Century Oncology Holdings, Inc..
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1503518/000104746916015101/a2229524z10-k.htm
Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.
ContinueRead positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.
ContinueRemove data columns and navigations in order to see much more filing content and tables in one view
ContinueRead both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
ContinueExport Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis
ContinueGet one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREEOur Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
ContinueOur Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
ContinueSee how over 70
Growth, Profitability and Financial Ratios perform over 10 Years